agosto 2020 – Página 133

Introducing Caliper Swiftsticks: The Newest Way to Consume CBD

DENVER, Aug. 6, 2020 /PRNewswire/ — Caliper Foods, an industry leader in water-soluble cannabinoid-infused consumer packaged goods and ingredients, introduced its newest product, Caliper Swiftsticks — a faster and tastier way to consume CBD. Caliper Swiftsticks are the first-to-market product of their kind and are sold in single-serve packets of deliciously flavored CBD powder that dissolves directly on the tongue. Swiftsticks are officially available on September 1st, and in celebration of National CBD Day on August 8^th, Caliper will be offering an early bird special for 10% off pre-orders.

Caliper is best known for its original fast-acting product, Caliper CBD, a flavorless water-soluble CBD powder that cleanly dissolves into any food or beverage. Sourced from U.S.-grown hemp, Caliper CBD is a reliable product that provides consistent and predictable results. Caliper Swiftsticks were designed for even easier on-the-go consumption, an innovation bred from consumer feedback and usage.

Free from THC and grassy aromas, Caliper Swiftsticks are available in three flavors: Mixed Berry, Cool Mint and Lemon Lime. Ideal for every lifestyle, each packet contains precisely 20mg of CBD that dissolves directly on your tongue. Swiftsticks are made with non-GMO ingredients, contain no artificial flavors and are free of calories, gluten, and fat. Additionally, the product does not contain any THC, and is non-psychoactive, so users can be assured that the Swiftsticks will provide consistent results without fear of an unintentional high.

Just like its sister product, Caliper CBD, Swiftsticks are backed by extensive science and research – adhering to rigorous testing for safety and potency. A clinical study conducted by Colorado State University found Caliper products are more bioavailable, with 6.5x more absorption in the first 15-minutes vs. traditional oil-soluble CBD products.

«We created Caliper Swiftsticks to provide our customers another easy and safe way to enjoy the benefits of CBD,» said Nicole Maione, General Manager of Caliper Consumer Goods. «Our products are always backed by science and go through rigorous testing for safety and potency. We pride ourselves on providing consistency and convenience unlike any other CBD product on the market. Whether you’re new to CBD or an enthusiast, Caliper is committed to making everyday life a little less achy, a little more restful, and a little less stressful.»

Caliper Swiftsticks will be sold online at www.trycaliper.com with prices ranging from $49.99 for a 30-pack to $84.00 for a 60-pack. Caliper Swiftsticks are also available for retail shelves and will be available for sale in a 2-pack for $6.99, 10-pack for $29.99, and 30-pack for $49.99 respectively. For more information and updates, visit the company’s website and follow along on Instagram @caliper.cbd.

About Caliper Foods
Caliper Foods is a functional foods company specializing in the processing, manufacturing and distribution of soluble cannabinoid-infused consumer packaged goods and ingredients. The company’s business-to-consumer arm (Caliper Consumer Goods) produces and sells its own line of dissolvable, hemp-derived CBD-infused products, including new Caliper CBD. The company’s business-to-business arm (Caliper Commercial Ingredients), produces a proprietary suite of application-specific formulations of water-soluble hemp-derived CBD that meet the quality control and documentation needs of experienced CPG experts. The company also has a relationship with Stillwater Brands, maker of some of Colorado’s leading THC- and CBD-infused edibles brands, including Ripple dissolvable cannabinoids, Stillwater Gummy Supplements and Stillwater Teas & Coffee. For more information, visit Caliperfoods.life.

Media Contact:
Yvonne Lo / Shelby Robinson
646.494.7521
244829@email4pr.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/introducing-caliper-swiftsticks-the-newest-way-to-consume-cbd-301107209.html

SOURCE Caliper Foods

New Academic Student Planner Designed to Deliver Significant Gains for Early Adolescents

PAWTUCKET, R.I., Aug. 6, 2020 /PRNewswire/ — Boston school psychologist, Ashley Daugherty, is proud to announce the launch of a unique academic organizational planner, Student Planner Plus, available for $30.00 at www.studentplannerplus.com. The robust planner is designed to help 5^th– 9^th grade students develop executive functioning skills, track assignments, increase independence and monitor progress toward future goals. It is also designed to assist parents who are struggling to support their children in these areas during these unpredictable times.

«Navigating the COVID-19 educational challenges with my students inspired me to create Student Planner Plus,» said Daugherty. «Students in 5^th -9^th grade are at a critical stage for developing executive functioning skills. It’s so crucial for early adolescents to cultivate these skills as their brains work to solidify lasting cognitive proficiencies. It’s my hope that the careful design of Student Planner Plus will be a game-changer for students and parents as students progress into independent, high-functioning young adults.»

Fifth through ninth grade is an important time in which students’ brains undergo rapid maturation. The prefrontal cortex, in particular, does not fully develop until one’s mid-twenties. This part of the brain is responsible for executive function skills such as attention, decision making, emotional regulation, self-monitoring, organization, planning and time management – all critical life competencies.

The Student Planner Plus features:

Weekly and monthly planning formats to write down assignments for each subject, estimate the time needed, and jot down the materials which will help them to do their best work
A template for students to reflect on the work they’ve done at the end of each week – rating efforts on a given week from one to five stars and reviewing homework assignments turned in on time
A goal planner for students to plan out weekends to allot time for school tasks, social events, and rest

«Student Planner Plus would be an invaluable asset during normal times, but with students needing to complete their work without the structure of a classroom setting, and parents trying to maintain their own work obligations from home, this planner is priceless,» said Chatham Anastasi, middle school teacher. «I see how students struggle to get assignments done on time. Student Plus Planner is an incredible solution to help them with these very age appropriate difficulties.»

For every planner sold, Student Planner Plus will donate a planner to a student who does not have the resources (either through school or home) to buy one. This is a small step we can take together to make the world a bit more equitable.

For more information regarding purchasing, donations and the BuyOneGiveOne model, visit www.studentplannerplus.com.

About Student Planner Plus

Student Planner Plus was created in 2020 by school psychologist, Ashley Daugherty, after the Covid-19 pandemic caused severe disruption to her students’ academic lives. She saw increased need to give students a way to stay on track while they did their daily school work from home. Daugherty, who recently acquired her Masters and Certificate of Advanced Graduate Studies in School Psychology from Northeastern University, currently works as a school psychologist at a Boston public middle school.

Media Contact:
Chris Raia
Duffy & Shanley
(o) 401.278.4445
(m) 240.463.8718
craia@duffyshanley.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/new-academic-student-planner-designed-to-deliver-significant-gains-for-early-adolescents-301107412.html

SOURCE Student Planner Plus

Global PD-L1 NSCLC Market: Insights, Epidemiology, Drugs and Players (2017-2030)

DUBLIN, Aug. 6, 2020 /PRNewswire/ — The «Programmed Death-Ligand 1 (PD-L1) Non-Small Cell Lung Cancer (NSCLC)-Market Insights, Epidemiology and Market Forecast -…

DUBLIN, Aug. 6, 2020 /PRNewswire/ — The «Programmed Death-Ligand 1 (PD-L1) Non-Small Cell Lung Cancer (NSCLC)-Market Insights, Epidemiology and Market Forecast – 2030» drug pipelines has been added to ResearchAndMarkets.com’s offering.

This report delivers an in-depth understanding of the PD-L1 NSCLC, historical and forecasted epidemiology as well as the PD-L1 NSCLC market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The market report provides current treatment practices, emerging drugs, PD-L1 NSCLC market share of the individual therapies, current and forecasted PD-L1 NSCLC market size from 2017 to 2030 segmented by seven major markets. The report also covers current PD-L1 NSCLC treatment practices/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses underlying potential of the market.

Epidemiology

PD-L1 NSCLC Epidemiology division provides the insights about historical and current PD-L1 NSCLC patient pool and forecasted trend for each seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The total NSCLC cases of patients by PD-L1 genetic biomarkers in the 7MM were observed to be 242,014 in 2017 which is expected grow during the study period, i.e., 2017-2030.

The disease epidemiology covered in the report provides historical as well as forecasted PD-L1 NSCLC Epidemiology[segmented as Total Incident Cases of NSCLC, Total Incident Cases of NSCLC Patients by Histology, Total Diagnosed Cases of NSCLC Patients by Stages, Total PD-L1-NSCLC Cases of Patients, and Treated PD-L1-NSCLC Patient Pool of NSCLC]scenario of PD-L1 NSCLC in the 7MM covering United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2017 to 2030.

Drug Chapters

Drug chapter segment of the PD-L1 NSCLC report encloses the detailed analysis of PD-L1 NSCLC marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the PD-L1 NSCLC clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

Keytruda (pembrolizumab): Merck

Keytruda is a PD-1 blocking antibody. It is mainly used for cancers that are advanced, have spread to other parts of the body or are not responding to other treatments. In some cancers, it is only given to patients whose tumors produce high levels of a protein known as PD-L1. This drug is also used to help prevent cancer from coming back after patients had surgery. It is approved for multiple types of cancer.

Keytruda is also approved as a single agent for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS 1%) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving Keytruda.

Imfinzi (Durvalumab): AstraZeneca

Imfinzi is a human monoclonal antibody that binds to PD-L1 and blocks the interaction of PD-L1 with PD-1 and CD80, countering the tumor’s immune-evading tactics and releasing the inhibition of immune responses. This product is given by intravenous infusion is approved in unresectable, Stage III NSCLC after chemoradiation therapy in the US, Japan, across the EU and in many other countries, based on the Phase III PACIFIC trial.

Opdivo (Nivolumab): Bristol-Myers Squibb

Opdivo by Bristol-Myers Squibb is a human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor PD-1, with immune checkpoint inhibitory and antineoplastic activities. It is a prescription medicine used to treat people with unresectable or metastatic melanoma, metastatic NSCLC, SCLC, advanced renal cell carcinoma, classical Hodgkin lymphoma, recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN), urothelial carcinoma, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer and hepatocellular carcinoma.

PD-L1 NSCLC Emerging Drugs

Canakinumab (ACZ885): Novartis Pharmaceuticals

Canakinumab is a product of Novartis Pharmaceuticals. This product was approved by the US Food and Drug Administration (FDA) with brand name Ilaris for the treatment of cryopyrin-associated periodic syndromes, which is a group of rare auto-inflammatory disorders. At present this product is being investigated for the treatment of NSCLC.

Canakinumab is an injectable human monoclonal antibody intended to bind to human interleukin-1 beta (IL-1 beta). Its mode of action is based on the neutralization of 1 signaling, resulting in suppression of inflammation in patients with disorders of autoimmune origin.

Avelumab (Bavencio): Merck KGaA and Pfizer

Avelumab is a fully human monoclonal antibody developed by Merck and Pfizer as a pharmaceutical drug for use in immunotherapy, originally for the treatment of NSCLC. Avelumab targets the PD-L1.Avelumab has also been shown to induce NK cell-mediated direct tumor cell lysis via antibody-dependent cell-mediated cytotoxicity (ADCC) in vitro. In November 2014, Merck (Germany), and Pfizer announced a strategic alliance to co-develop and co-commercialize Avelumab.

Libtayo (Cemiplimab): Regeneron Pharmaceuticals

Libtayo is a fully-human monoclonal antibody designed as an immune checkpoint inhibitor of the programmed cell death protein-1 (PD-1), prescribed as monotherapy and combination therapy in first-line patients with advanced NSCLC. This drug is currently in two phase III trial recruiting patients in first-line NSCLC.

M7824 (Bintrafusp alfa): GlaxoSmithKline/Merck KGaA

M7824 (Bintrafusp alfa) is an investigational bifunctional immunotherapy that is designed to combine a TGF- trap with the anti-PD-L1 mechanism in one fusion protein, targeting both pathways aim to control tumor growth by potentially restoring and enhancing anti-tumor responses. This drug is currently in Phase I studies for solid tumors, as well as a randomized Phase II trial to investigate M7824 compared with pembrolizumab as a first-line treatment in patients with PD-L1 expressing advanced NSCLC.

Market Outlook

Currently PD-1/PD-L1 blocking antibodies therapy is recommended for the patients showing PD-L1 expressions. In recent years, immunotherapy has revolutionized and changed the standard of care in patients with NSCLC. Immune checkpoint inhibitors, fundamentally those that act by blocking PD-1 and its ligand, the PD-L1, have emerged as novel treatment strategies in NSCLC, demonstrating undoubted superiority over chemotherapy in terms of efficacy.

Treatments for patients with advanced NSCLC are palliative, and thus intended to prolong survival and preserve quality of life for as long as possible, while minimizing the side effects due to treatment. Immune checkpoint inhibitors targeting either programmed cell death protein 1 (PD-1) or programmed cell death ligand 1 (PD-L1) have become routinely part of the clinical approach for management of NSCLC. Specifically, patients with PD-L1 expression 50% are typically offered monotherapy with the anti-PD-1 antibody pembrolizumab, although some with rapidly progressing or very extensive disease may be treated with a platinum doublet chemotherapy plus pembrolizumab. For patients with PD-L1 expression < 50%, the combination of a platinum-doublet chemotherapy and pembrolizumab is standard. Choice of chemotherapy, for those receiving it is mainly influenced by histology.

So, treatment approach of PD-L1 expressed NSCLC is mainly depend on the use of immune checkpoint inhibitors, but to increase the efficacy of the treatment several companies are developing combinational products for the treatment of PD-L NSCLC.

Key Findings

According to the publisher PD-L1 NSCLC market in the 7MM is expected to change in the study period 2017-2030. The therapeutic market of PD-L1 NSCLC in seven major markets was found to be USD 6,536 million in 2017 which is expected to increase during study period (2017-2030).

The United States Market Outlook

In 2017, the total market size of PD-L1 NSCLC therapies was found to be USD 3,714 million in the United States which is expected to increase in the study period (2017-2030).

EU-5 Countries: Market Outlook

In 2017, the total market size of PD-L1 NSCLC therapies was found to be USD 1,842 million in the EU-5 countries which is expected to increase in the study period (2017-2030).

Japan Market Outlook

The total market size of PD-L1 NSCLC therapies in Japan was found to be USD 980 million in 2017.

Pipeline Development Activities

The drugs which are in pipeline include:

Canakinumab (ACZ885) (Novartis Pharmaceuticals): Phase III
Opdivo (nivolumab) Ipilimumab (Bristol-Myers Squibb):Phase III
Imfinzi(durvalumab) Tremelimumab (AstraZeneca): Phase III
M7824 (Bintrafusp alfa) (GlaxoSmithKline/Merck KGaA): Phase III
Libtayo (Cemiplimab) (Regeneron Pharmaceuticals): Phase III
Avelumab (Bavencio)(Merck KGaA and Pfizer): Phase III

Key Points

Bristol-Myers Squibb,Opdivo in combination withYervoy(ipilimumab) got Priority Review by the US FDA for the first-line treatment of patients with metastatic or recurrent NSCLC with no EGFR or ALK genomic tumor aberrations. The US FDA has granted the application Priority Review with a Prescription Drug User Fee Act (PDUFA) goal date of May 15, 2020.
Also, in April 2020, the US FDA granted Priority Review to the combination of Opdivo plus Yervoy with limited chemotherapy as a first-line treatment of patients with metastatic or NSCLC who have noEGFR orALKgenomic tumor aberrations. The Prescription Drug-Free User Act target action date is set as August 6, 2020, and the combination was granted Fast Track designation.
AstraZeneca is also investigating this product ina broad development programin combination with tremelimumab, an anti-CTLA4 monoclonal antibody and potential new medicine, as a treatment for patients with NSCLC, SCLC, and several other types of cancers.
Avelumab has also been shown to induce NK cell-mediated direct tumor cell lysis via antibody-dependent cell-mediated cytotoxicity (ADCC) in vitro. In November 2014, Merck (Germany), and Pfizer announced a strategic alliance to co-develop and co-commercialize Avelumab.

Drugs Uptake

Keytruda is expected to major share from the overall market of PD-L1 NSCLC due to physician’s familiarities and established clinical profile. On the other hand, Opdivo is expected to take second highest share from the market due to its dominancy in second-line line setting.

Access and Reimbursement Scenario

As per the recommendation of some drugs by NICE which are approved for NSCLC, theaccess and reimbursement scenario for therapies in the UK are listed as:

In July 2018, Keytruda was recommended for, untreated PD L1-positive metastatic NSCLC in adults whose tumors express PD L1 (with at least a 50% tumor proportion score) and have no EGFR- or ALK-positive mutations.
In January 2017, Keytruda is recommended for treating locally advanced or metastatic PD L1 positive NSCLC in adults who have had at least one chemotherapy (and targeted treatment if they have an EGFR- or ALK-positive tumor).
In May 2019, Durvalumab is recommended for treating locally advanced unresectable NSCLC in adults whose tumors express PD L1 on at least 1% of tumor cells and whose disease has not progressed after platinum-based chemoradiation.
It was stated by NICE that Atezolizumab +bevacizumab is recommended for metastatic NSCLC in adults who have not had treatment for their metastatic NSCLC before and whose PD-L1 tumor proportion score is between 0% and 49%.

KOL – Views

To keep up with current market trends, we take KOLs and SME’s opinion working in PD-L1 NSCLC domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or PD-L1 NSCLC market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the PD-L1 NSCLC Market by using various Competitive Intelligence tools that includes – SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

The report covers the descriptive overview of PD-L1 NSCLC, explaining its causes, signs and symptoms, pathophysiology and currently available therapies.
Comprehensive insight has been provided into thePD-L1 NSCLC epidemiology and treatment in the 7MM.
Additionally, an all-inclusive account of both the current and emerging therapies for PD-L1 NSCLC is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
A detailed review of PD-L1 NSCLC market; historical and forecasted is included in the report, covering drug outreach in the 7MM.
The report provides an edge while developing business strategies, by understanding trends shaping and driving the global PD-L1 NSCLC market.

Report Highlights

In the coming years, PD-L1 NSCLC market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
The companies and academics are working to assess challenges and seek opportunities that could influence PD-L1 NSCLC R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
Major players are involved in developing therapies for PD-L1 NSCLC. Launch of emerging therapies, will significantly impact the PD-L1 NSCLC market.
A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for PD-L1 NSCLC.
In-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Companies Mentioned

AstraZeneca
Bristol-Myers Squibb
Genentech
GlaxoSmithKline
Hoffmann-La Roche
Merck
Novartis Pharmaceuticals
Pfizer
Regeneron Pharmaceuticals

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/8lr9uh

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/global-pd-l1-nsclc-market-insights-epidemiology-drugs-and-players-2017-2030-301107521.html

SOURCE Research and Markets

European Patent Office Grants Cellect Biotechnology Pivotal Patent for Stem Cells Activation

TEL AVIV, Israel, Aug. 6, 2020 /PRNewswire/ — Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative technology which enables the functional selection of stem cells, today announced that it has significantly strengthened its Intellectual Property (IP) portfolio as European Patent Application No. 14851547.1 has been granted. The patent will be set to expire in October 7, 2034, subject to patent term adjustment or extension.

«This is a pivotal…

«This is a pivotal event for Cellect and perhaps one of the most crucial developments for us as we have secured IP protection over the second component of the Apograft™ effects – the activation of the stem and progenitor cells,» commented Dr. Shai Yarkoni, Chief Executive Officer. «While the extensive issued patents cover the accurate elimination (negative selection) of the mature cells and therefor enables SAFETY, this patent covers the increased ACTIVITY (positive selection=efficacy) of the regenerative capacity of the stem and progenitor cells. Combined with our previously issued patents, our IP now cover the dual effects of the apoptotic proteins with a single, robust, and cost-effective process that is achieved outside of the patient’s body. The clinical and economic benefits are multi-fold as we have demonstrated increased safety and efficacy of the cell product by developing a robust, non-expensive and user-friendly process and product.

«Our actions over the past few years to strengthen our IP, culminating with this very important achievement, has been a core component of our business strategy and has far-reaching revenue and business development activities. While some of these discussions are and have been underway for some time with global leaders in cell therapy, it’s quite obvious we are now in a much stronger position to leverage our innovation to extract tremendous value.»

The patent, which was also recently approved in Australia and Israel, includes a cell-based product and a method of manufacturing a stem and progenitor cell population with enhanced activity by incubation with an apoptotic ligand at specific concentrations and exposure times. The Company has an extensive Intellectual Property (IP) portfolio, with 65 patents in nine patent families, with 45 already granted/allowed patents, 18 pending/in examination and two Patent Cooperation Treaty (PCT) applications. The Company plans to continue expanding and protecting its global IP to monetize its investments, either internally or externally, and to create further barriers to entry.

About Cellect Biotechnology Ltd.

Cellect Biotechnology (APOP) has developed a breakthrough technology, for the selection of stem cells from any given tissue, that aims to improve a variety of stem cell-based therapies.

The Company’s technology is expected to provide researchers, clinical community and pharma companies with the tools to rapidly isolate stem cells in quantity and quality allowing stem cell-based treatments and procedures in a wide variety of applications in regenerative medicine. The Company’s current clinical trial is aimed at bone marrow transplantations in cancer treatment.

Forward Looking Statements

This press release contains forward-looking statements about the Company’s expectations, beliefs and intentions. Forward-looking statements can be identified by the use of forward-looking words such as «believe», «expect», «intend», «plan», «may», «should», «could», «might», «seek», «target», «will», «project», «forecast», «continue» or «anticipate» or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. For example, forward-looking statements are used in this press release when we discuss Cellect’s expectations regarding timing of the commencement of its planned U.S. clinical trial and its plan to reduce operating costs. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In addition, historical results or conclusions from scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: the Company’s history of losses and needs for additional capital to fund its operations and its inability to obtain additional capital on acceptable terms, or at all; the Company’s ability to continue as a going concern; uncertainties of cash flows and inability to meet working capital needs; the Company’s ability to obtain regulatory approvals; the Company’s ability to obtain favorable pre-clinical and clinical trial results; the Company’s technology may not be validated and its methods may not be accepted by the scientific community; difficulties enrolling patients in the Company’s clinical trials; the ability to timely source adequate supply of FasL; risks resulting from unforeseen side effects; the Company’s ability to establish and maintain strategic partnerships and other corporate collaborations; the scope of protection the Company is able to establish and maintain for intellectual property rights and its ability to operate its business without infringing the intellectual property rights of others; competitive companies, technologies and the Company’s industry; unforeseen scientific difficulties may develop with the Company’s technology; the Company’s ability to retain or attract key employees whose knowledge is essential to the development of its products; and the Company’s ability to pursue any strategic transaction or that any transaction, if pursued, will be completed. Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading «Risk Factors» in Cellect Biotechnology Ltd.’s Annual Report on Form 20-F for the fiscal year ended December 31, 2019 filed with the U.S. Securities and Exchange Commission, or SEC, which is available on the SEC’s website, www.sec.gov, and in the Company’s periodic filings with the SEC.

Contact
Cellect Biotechnology Ltd.
Eyal Leibovitz, Chief Financial Officer
www.cellect.co
+972-9-974-1444

EVC Group LLC
Michael Polyviou
(732) 933-2754
mpolyviou@evcgroup.com

View original content:http://www.prnewswire.com/news-releases/european-patent-office-grants-cellect-biotechnology-pivotal-patent-for-stem-cells-activation-301107622.html

SOURCE Cellect Biotechnology Ltd.

Curaleaf’s Select Brand Expands Into Florida Medical Market

America’s #1 Cannabis Oil Brand is Now Available in 12 States

WAKEFIELD, Mass., Aug. 6, 2020 /PRNewswire/ — Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) («Curaleaf» or the «Company»), a leading vertically integrated cannabis operator in the United States, announced today that it would launch its line of Select brand products into Florida, starting with its Select Elite Live cartridges.

Select, known as America’s #1 Cannabis Oil Brand, has been on a path of rapid expansion since Curaleaf acquired it in February 2020. Select products are now available at over 950 independent dispensaries across 12 states, including Arizona, California, Colorado, Connecticut, Florida, Maryland, Michigan, Nevada, Oklahoma, Oregon, Massachusetts, and Maine. The Select brand will continue to expand across the U.S., with its launch into Ohio’s medical market later this month.

As a recognized industry leader, Select is committed to maintaining the highest quality control standards and testing transparency and delivering the best experience possible. Select Elite Live is the brand’s new enhanced live resin product, which combines high-quality THC oil and live resin high-terpene extract. Curaleaf looks forward to unveiling more of Select’s leading product offerings to Florida’s medical patients soon, including the brand’s best-selling high potency broad spectrum Select Elite cartridges, later this year.

«With Select’s expansion into Florida, we are making excellent progress in creating the first nationally recognized cannabis brand in the U.S.,» said Joe Bayern, President at Curaleaf. «Beyond that, it allows us to better serve our medical patients with a variety of products that undergo the most stringent and progressive oil testing standards in the industry.»

Florida’s continued growth in patient registration makes it one of the nation’s fastest-growing medical cannabis markets in the country. Currently, there are over 377,000 medical patients enrolled in the Florida program – about 1.7% of the state’s population – with approximately 5,000 new patients joining each week.

By way of the Medical Use of Medical Marijuana Act, vertically integrated (seed to sale) operations are required in the state. Therefore, Select products will be sold exclusively at Curaleaf’s 28 dispensary locations in Florida. Last month, Curaleaf launched its new Sublingual Tablets – a first-to-market product solely available to Florida patients. These cube-shaped, berry-flavored bites provide a discreet, sugar-free yet fruity alternative form of medication. Sold in 30-piece jars, Curaleaf Sublingual Tablets contain 5mg of high-quality cannabis oil per piece, which allows patients to manage their treatment plan with confidence and ease. To see Curaleaf’s dispensary locations in Florida, please visit https://curaleaf.com/locations/#florida.

About Curaleaf Holdings, Inc.
Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) («Curaleaf») is a leading vertically integrated U.S. multi-state cannabis operator with a mission to improve lives by providing clarity around cannabis and confidence around consumption. As a high-growth cannabis company known for quality, expertise and reliability, the company and its brands, including Curaleaf and Select, provide industry-leading service, product selection and accessibility across the medical and adult-use markets. Curaleaf currently operates in 23 states with 88 dispensaries, 22 cultivation sites and over 30 processing sites, and employs over 3,000 people across the United States. Curaleaf is listed on the Canadian Securities Exchange under the symbol CURA and trades on the OTCQX market under the symbol CURLF. For more information please visit www.curaleaf.com.

INVESTOR CONTACT
Curaleaf Holdings, Inc.
Dan Foley, VP, Finance and Investor Relations
IR@curaleaf.com

MEDIA CONTACT
Curaleaf Holdings, Inc.
Tracy Brady, VP Corporate Communications
media@curaleaf.com

FORWARD-LOOKING STATEMENTS
This media advisory contains forward–looking statements and forward–looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward–looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as «plans», «expects» or, «proposed», «is expected», «intends», «anticipates», «or «believes», or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, would, or might occur or be achieved. More particularly and without limitation, this news release contains forward–looking statements and information concerning the expansion of the Select brand of products into Florida and Ohio. Such forward-looking statements and information reflect management’s current beliefs and are based on assumptions made by and information currently available to the company with respect to the matter described in this new release. Forward-looking statements involve risks and uncertainties, which are based on current expectations as of the date of this release and subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Additional information about these assumptions and risks and uncertainties is contained under «Risk Factors and Uncertainties» in the Company’s latest annual information form filed September 23, 2019, which is available under the Company’s SEDAR profile at www.sedar.com, and in other filings that the Company has made and may make with applicable securities authorities in the future. Forward-looking statements contained herein are made only as to the date of this press release, and we undertake no obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. The Canadian Securities Exchange has not reviewed, approved, or disapproved the content of this news release.

View original content:http://www.prnewswire.com/news-releases/curaleafs-select-brand-expands-into-florida-medical-market-301107298.html

SOURCE Curaleaf Holdings, Inc.

Tru Optik and SpotX Partnership Utilizes Advanced Data Targeting to Help Top Food Brand Engage Audience through CTV

STAMFORD, Conn., Aug. 6, 2020 /PRNewswire-PRWeb/ — Consumer adoption of connected TV (CTV) has grown quickly, with 50% of TV households now watching streamed television — one-third of which can only be reached by CTV as they do not subscribe to cable. CTV has become a can’t-miss opportunity for advertisers thanks to its highly engaged and targetable audiences. Yet, many still face the challenge of establishing a scalable audience strategy across numerous publishers and a diverse landscape of connected devices.

With this change in content consumption, Tru Optik, powered by the largest household graph across the connected media ecosystem, partnered with SpotX and Havas Media to help a leading food brand create a data-driven and efficient campaign that reached the brand’s target audience through contextual CTV placements.

SpotX mitigates this fragmentation challenge by providing a centralized access point for CTV inventory, as it works with 97% of premium ad-supported over-the-top (OTT) providers and reaches over 50 million US households.

Coupled with the data enablement capabilities of SpotX’s Audience Management Engine (AME), advertisers are able to take advantage of an integration with an array of first- and third-party data providers, distributed by Tru Optik, to precisely target unique audience segments at scale. As the use of private marketplaces grows, it is more important than ever that advertisers consider a data strategy with the supply side. Working with a supply partner to target audiences allows advertisers to increase access to premium inventory, improve forecasting, and bring incremental value to their campaigns.

Havas Media wanted to help its client reach a target audience of women aged 25-54 through CTV, while maintaining scale. The goal of the campaign was to efficiently drive frequency against the target audience within contextually relevant environments, as measured by the in-demo audience reached.

«SpotX was an invaluable partner in helping us activate audience data and gain a holistic view of available CTV inventory. The campaign delivered impressive reach and we were able to efficiently engage the desired audience in a meaningful way,» said Danielle Farrugia, SVP, Biddable Media, Havas Media.

SpotX and Havas Media were able to launch a data-driven CTV campaign designed to reach the brand’s target audience at scale. Leveraging Tru Optik’s Data Marketplace, SpotX was able to activate previously unavailable data segments through AME, forecast available inventory for the campaign, and ensure it could deliver against the full budget.

This data activation allowed for advanced audience targeting that reached women aged 25-54 who are primary grocery shoppers, health conscious, and home chefs. Contextual targeting was also applied to optimize frequency, with the campaign running during cooking and female-driven lifestyle or entertainment content.

«Quality data can make or break a campaign. The depth of our relationships with media owners and data providers such as Tru Optik allows us to match advertisers’ desired data directly to publisher inventory through Audience Management Engine, thus increasing forecasting and planning visibility to help advertisers efficiently reach their audience,» added Kristen Williams, VP of Strategic Partnerships, SpotX.

The campaign was extremely successful and was able to deliver against the full campaign budget. With 6.3 million impressions of targeted scale on premium CTV ad inventory across the desired audience segments and securing over 85% in-demo delivery well within the target eCPM range, the brand opted to continue working with Tru Optik and SpotX to re-launch.

«Partnering with SpotX and Havas Media to facilitate accurate, scalable, and privacy-compliant audience targeting across CTV is core to Tru Optik’s long-standing value proposition across the ecosystem. We look forward to continuing to work with both of them to help drive exceptional results for brands and marketers.» added Michelle Swanston, Chief Client Officer, Tru Optik.

About Tru Optik:
Tru Optik identity resolution powers the streaming media ecosystem. Tru Optik’s patented Household Graph™ of more than 80 million U.S. homes enables the world’s leading brands, agencies, media companies, and platforms to engage consumers across OTT, streaming audio, and gaming with unmatched scale, accuracy and privacy compliance. To learn more about Tru Optik visit: http://www.truoptik.com.

About SpotX:
SpotX is the leading video advertising platform shaping digital video and the future of TV globally. The company’s solutions enable media owners to monetize content across all screens and streams while providing advertisers with direct access to brand-safe, premium inventory. With best-in-class technology purpose-built for video, SpotX’s trusted, GDPR/CCPA-compliant solutions are employed by some of the largest media owners in the world including A+E Networks, Crackle Plus, The CW Network, Dentsu CCI, Discovery, Electronic Arts, Fox Corporation, fuboTV, Gannett, Microsoft, Newsy, Pluto TV, Roku, Sling TV, and Vudu. In the US, SpotX works with nearly all major OTT stakeholders and reaches 4 out of 5 viewers of ad-supported CTV, or 50 million households. In early 2019, SpotX acquired Yospace which powers server-side ad insertion (SSAI) for all live and video on demand content streamed to connected devices. SpotX is a subsidiary of Bertelsmann’s RTL Group and is headquartered in Denver with 12 offices throughout the US, EMEA, and APAC regions. Learn more at http://www.spotx.tv.

SOURCE Tru Optik

The Rockefeller Foundation Announces 10 Finalists for the Food System Vision Prize

NEW YORK, Aug. 6, 2020 /PRNewswire/ — The Rockefeller Foundation, in partnership with SecondMuse and OpenIDEO, today announced the Top 10 Finalists for the Food System Vision Prize. These Finalists were selected from a pool of more than 1,300 applicants from 110 countries, all seeking to develop a…

The Top 10 Finalists, whose visions focus on Canada, China, India, Kenya, the Netherlands, Nigeria, Peru, and the U.S., were chosen among 76 Semi-Finalists. They were selected based on their potential to inspire real, positive and bold transformation of a specific food system that is actionable, concrete and believed to be attainable by 2050. These Visions aim to tackle challenges tied to six themes: environment, diets, economics, culture, technology, and policy.

The Food System Vision Prize was launched nearly a year ago as an invitation for organizations, institutions, companies, universities and governments across the globe to develop actionable solutions for the food systems of tomorrow. An esteemed panel of Judges, including food system leaders from across academia, civil society and the private sector, reviewed the Semi-Finalist submissions and selected the 10 Finalists.

«The inspiring Visions they have put forward paint a picture of a more hopeful future food system – one that is equitable, sustainable and can transform our planet and improve the diets and health of people across the globe,» said Dr. Rajiv J. Shah, President of The Rockefeller Foundation.

The Top 10 Finalists for the Food System Vision Prize are:

7Gen Food System: Led by the Sicangu Lakota people, this Vision for the Rosebud Indian Reservation of South Dakota, USA outlines a regenerative agricultural system that creates economic opportunities for tribal members; increases the accessibility of locally produced, nutrient-dense foods; and re-establishes the Lakota as primary stewards of the lands [Lead Organization: Sicangu Community Development Corporation].
Arakunomics: Focusing on the regions of Araku, Wardha, and New Delhi, India, this Vision empowers tribal communities and seeks to ensure environmental sustainability, fair profits for farmers, and food and nutrition security for all [Lead Organization: Naandi Foundation].
Eat Right: This Vision from New Delhi, India looks to create a national movement towards healthier diets through a systems-based approach of reducing food waste; improving hygiene and sanitation across the value chain; and increasing access to and affordability of healthy foods [Lead Organization: Food Safety and Standards Authority of India, Ministry of Health and Family Welfare, Government of India].
Food Innovation Nervecenter: This Vision from Lagos, Nigeria identifies six key food challenges for the region, from food waste to aging farmers, and outlines a multi-faceted plan to build a more regenerative and nourishing food system [Lead Organization: Darkpore Media Africa LTD].
From Mama’s Kitchen to Metropolitan Beijing: This Vision from Beijing, China imagines a plant-based dietary transformation for the world’s most populous nation, contributing to reductions in greenhouse gas emissions and pollution [Lead Organizations: Good Food Fund of the China Biodiversity Conservation & Green Development Foundation].
Kwayeskastasowin Wahkohtowin: Led by local First Nations communities, this Vision from Manitoba, Canada aims to create a just and sustainable agrifood system while addressing the process of decolonization and reconciliation between Indigenous and settler populations [Lead Organization: Natural Systems Agriculture Laboratory, University of Manitoba].
Lima 2035: This Vision for Lima, Peru imagines a regenerative and nourishing food oasis by 2035, with the aim of securing climate-resilient running water for all in Lima’s fragile desert environment [Lead Organization: International Potato Center].
Re-rooting the Dutch Food System – From More to Better: This Vision from the Netherlands outlines a transformed, circular Dutch food system that safeguards natural resources, promotes a healthier and more sustainable plant-based diet, and recycles unavoidable losses and wastes [Lead Organization: Wageningen University & Research].
Restoring Nairobi to «A Place of Cool Waters»: This Vision for Nairobi, Kenya aims to develop a more equitable, just and sustainable urban space, where access to nutritious food is a reality for everyone [Lead Organization: African Population and Health Research Center].
Stone Barns Center: This Vision from the Hudson Valley in New York, U.S. seeks to bring about a new food culture—rooted in the ecological, nutritional and communal potential of organic agriculture—through groundbreaking culinary experimentation [Lead Organization: Stone Barns Center for Food and Agriculture].

«These Visions are a great example of the importance of—and opportunity for—innovation during a crisis. This is even more urgent given the severe stresses placed on food systems as a result of the Covid-19 pandemic,» said Roy Steiner, Senior Vice President of the Food Initiative at The Rockefeller Foundation. «We look forward to seeing how they move their ideas from Vision to action.»

In September, the Finalists will advance to a three-month virtual Accelerator phase during which they will receive support to further refine their Visions and find pathways for implementation and impact. The Accelerator will focus on stakeholder engagement, storytelling, communications, and action planning through virtual programming, one-on-one mentorship and customized support. Each Finalist is eligible to become a Top Visionary and to receive a prize of $200,000 USD. Top Visionaries will be announced in December 2020.

«Visions teams took a systems approach to include diverse voices while incorporating social and environmental priorities. These Finalists give us reason for optimism, offering exciting and tangible possibilities to transform food systems, from production to consumption, to ensure a healthy and sustainable future for people and our planet,» said Maria Balcazar Tellez, Program Manager and Food System Vision Prize Lead at SecondMuse.

«Systems change means going beyond a few organizations working in silos. This Prize supports Visions rooted in local communities, while building a global network for teams to connect, learn and gain inspiration from each other,» says Matt Ridenour, Food Portfolio Lead at OpenIDEO.

More information about the Finalists and their Visions can be found at the Food System Vision Prize website: https://www.foodsystemvisionprize.org/

View original content:http://www.prnewswire.com/news-releases/the-rockefeller-foundation-announces-10-finalists-for-the-food-system-vision-prize-301107643.html

SOURCE The Rockefeller Foundation

Flora™ Debuts in U.S. with New Flora Plant Butter

HACKENSACK, N.J., Aug. 6, 2020 /PRNewswire/ — Upfield, the world’s leading producer of plant-based spreads and plant butters, today introduced its newest plant butter brand, Flora™, with the launch of Flora Plant Butter in the United States. Flora Plant Butter is a vegan, dairy free, gluten free, and non-GMO plant butter with a rich and creamy taste and which consumers can use 1:1 in baking and cooking but is made with plant-based oils, and no artificial flavors or preservatives. Flora Plant Butter is packaged in paper wrapping, not plastic, making it a more environmentally responsible choice for consumers looking to reduce their imprint on our planet through sustainable foods, without sacrificing taste.

«Flora is a culinary-inspired premium brand that brings a rich heritage of chef experience from markets around the world, and it is a thrill to bring this new brand to American consumers,» said Bernice Chao, brand lead, Flora, Upfield North America. «We are a product loved by chefs that can be used by home cooks and bakers who are looking to put a twist on traditional recipes with a dairy-free and great tasting ingredient.»

Flora Plant Butter
Flora Plant Butter is made from a blend of responsibly sourced palm, sunflower and canola oils, which give it a rich and creamy texture. It can be used like dairy butter 1:1 in cooking and baking, or spreading, without compromising buttery taste or performance.

«We are deeply passionate about creating new foods that will change our world because they are better for you and better for our planet,» continued Chao. «With Flora Plant Butter we have done just that. First, as a plant butter that is a vegan and non-dairy product that offers a suitable option to help consumers meet their dietary or lifestyle needs. Second, as an environmentally conscious brand that is leading the way with 100% plastic-free paper packaging.»

Flora Plant Butter comes in plastic-free FSC* certified parchment paper. The product has a suggested retail price of $3.49 and comes in salted and unsalted varieties in 8.8 oz. brick format. Flora Plant Butter is now available at select Kroger stores. For more information, please visit www.flora.com/en-us/floraplant.

*Forest Stewardship Council

About Upfield
The Upfield mission is to make people healthier and happier with great tasting, plant-based nutrition products that are better for the planet. Upfield is the leading producer of plant-based spreads and plant butter in North America, with iconic brands such as Country Crock®, Country Crock® Plant Butter, Becel®, I Can’t Believe It’s Not Butter!®, Imperial® and now Flora™. Upfield is also pleased to offer Violife® plant-based cheeses following its acquisition of Arivia earlier this year. The company is leading in delivering better for you products that are great tasting and have superior quality and help us deliver on our mission to create a «Better Plant-based Future.» For more information, visit www.Upfield.com.

View original content to download multimedia:http://www.prnewswire.com/news-releases/flora-debuts-in-us-with-new-flora-plant-butter-301107409.html

SOURCE Flora

Douglas Borthwick Wins Top Attorney Award

SANTA ANA, Calif., Aug. 6, 2020 /PRNewswire/ — Attorney.com is pleased to announce the selection of Attorney Douglas Borthwick for the 2019 Top Attorney Award. Attorney Borthwick was chosen from over 300 Divorce and Family Law Attorneys in San Bernardino County.

Top Attorney Award Winners have to demonstrate a consistent track record of successful transactions and satisfied clients. Only 1 in 50 attorneys meet Attorney.com’s…

Top Attorney Award Winners have to demonstrate a consistent track record of successful transactions and satisfied clients. Only 1 in 50 attorneys meet Attorney.com’s exacting review requirements. Strong client ratings are an especially important component of Attorney.com’s review process.

Due to his outstanding accomplishments and expertise in the field of divorce and family law, Attorney Borthwick is a valued member of the National Association of Distinguished Counsel. Aside from exhibiting an outstanding success rate in several binding and non-binding arbitrations and mediations, Attorney Borthwick comes highly recommended by other attorneys in his field.

Based on his high peer review ratings, Attorney Borthwick is recognized as an AV preeminent rated attorney by Martindale-Hubbel, is Superb rated by Avvo, and holds an esteemed membership with the Academy of Lawyers.

«As the principal attorney in one of the fastest growing law firms in the US, Attorney Borthwick is committed to his clients, even offering house calls and weekend consultations,» notes Gerald Gorman, CEO of Attorney.com. «We pride ourselves on rewarding only the best in the legal profession, and Attorney Borthwick is among the prestigious class of divorce and family law attorneys who are most deserving of our Top Attorney Award.»

Visit https://www.attorney.com/ for more information about the Top Attorney Awards.

To learn more about Law Offices of Douglas Borthwick, visit www.borthwicklawyer.com.
Also visit: https://calbizjournal.com/attorney-douglas-borthwick/
Also visit: https://www.acq-intl.com/issues/2018-Leading-Adviser-Supplement/32/

Media Contact: John Walter
Phone: 714-564-9400

Contact Douglas M. Borthwick
Law Offices of Douglas Borthwick
Telephone: 714-654-6742
Firm website: www.borthwicklawyer.com

The Law Office of Attorney Douglas Borthwick can be reached at (714) 654-6742 and https://borthwicklawyer.com/

View original content to download multimedia:http://www.prnewswire.com/news-releases/douglas-borthwick-wins-top-attorney-award-301107625.html

SOURCE Law Offices of Douglas Borthwick

Chipotle Leverages Its Real Change Feature To Support Its Pledge For Equality

NEWPORT BEACH, Calif., Aug. 6, 2020 /PRNewswire/ — Chipotle Mexican Grill (NYSE: CMG) today announced its new real change feature on the Chipotle app and Chipotle.com will spotlight the Thurgood Marshall College Fund (TMCF), an American non-profit organization that supports and represents students attending its 47 member-schools that include publicly-supported historically black colleges and universities, (HBCUs) medical schools, and law schools. From August…

To increase its diversity pipeline, Chipotle will also partner with the Thurgood Marshall College Fund to utilize TMCF’s Talent Sourcing Program to identify and develop diverse talent. With student loan debt disproportionately impacting people of color, Chipotle is easing access to a college education for its employees, launching debt-free degrees last year with 100% of tuition costs covered upfront in addition to the Company’s existing tuition reimbursement program. Intentional in its efforts to reset the organization over the past few years, Chipotle has been tracking its annual business results against its progress on diversifying its workforce, and all metrics have indicated that diversity is not only good for culture, but also business. Chipotle made a public commitment towards equality in June and continues to be transparent in its progress, providing updates here.

«It is important that we put our words into action and share our progress on combatting the injustices taking place today,» said Marissa Andrada, Chief Diversity, Inclusion and People Officer, Chipotle. «Cultivating a better world takes commitment from all of us and I’m encouraged by the accomplishments to date and eager to see how much more we can achieve together. It is imperative that we keep the conversation going.»

«We are extremely grateful that Chipotle will utilize our Talent Sourcing Program to identify talent at our member-school campuses,» said TMCF President and CEO Harry L. Williams. «Chipotle’s strong support of our mission will help us continue the critical and necessary work of ensuring that students have access to a higher education and new career opportunities.»

After introduction of the round up technology on Chipotle’s app only weeks ago, over 1.4 million guests have contributed on average $.45 with each order, totaling approximately $1,000,000, towards the first spotlight organization, the National Urban League. In June, Chipotle pledged $1,000,000 in support of organizations advocating against systemic racism, beginning with a commitment of $500,000 to the National Urban League. Chipotle will source feedback from its 91,000 employees to identify future organizations to highlight within the program.

To learn more about opportunities within Chipotle’s organization, visit https://jobs.chipotle.com/

ABOUT CHIPOTLE
Chipotle Mexican Grill, Inc. (NYSE: CMG) is cultivating a better world by serving responsibly sourced, classically-cooked, real food with wholesome ingredients without artificial colors, flavors or preservatives. Chipotle had over 2,650 restaurants as of June 30, 2020, in the United States, Canada, the United Kingdom, France and Germany and is the only restaurant company of its size that owns and operates all its restaurants. With more than 91,000 employees passionate about providing a great guest experience, Chipotle is a longtime leader and innovator in the food industry. Chipotle is committed to making its food more accessible to everyone while continuing to be a brand with a demonstrated purpose as it leads the way in digital, technology and sustainable business practices. Steve Ells, founder and former executive chairman, first opened Chipotle with a single restaurant in Denver, Colorado in 1993. For more information or to place an order online, visit WWW.CHIPOTLE.COM.

ABOUT THE THURGOOD MARSHALL COLLEGE FUND (TMCF):
Established in 1987, the Thurgood Marshall College Fund (TMCF) is the nation’s largest organization exclusively representing the Black College Community. TMCF member-schools include the publicly-supported Historically Black Colleges and Universities and Predominantly Black Institutions, enrolling nearly 80% of all students attending black colleges and universities. Through scholarships, capacity building and research initiatives, innovative programs, and strategic partnerships, TMCF is a vital resource in the PK-12 and higher education space. The organization is also the source of top employers seeking top talent for competitive internships and good jobs.

TMCF is a 501(c)(3) tax-exempt, charitable organization. For more information about TMCF, visit: www.tmcf.org.

View original content to download multimedia:http://www.prnewswire.com/news-releases/chipotle-leverages-its-real-change-feature-to-support-its-pledge-for-equality-301107497.html

SOURCE Chipotle Mexican Grill, Inc.